2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-167702
    (Rac)-Acetoxyvalerenic acid 81397-67-3 98%
    (Rac)-Acetoxyvalerenic acid is a derivative of valerenic acid that acts as a GABA (A) receptor modulator, potentially providing sedative and sleep-enhancing effects. (Rac)-Acetoxyvalerenic acid exhibits slower permeability across the blood-brain barrier compared to diazepam, indicating that its transport may rely on an unidentified pathway rather than transcellular passive diffusion.
    (Rac)-Acetoxyvalerenic acid
  • HY-167709
    Azacosterol 313-05-3 98%
    Azacosterol (20.25-Diazacholesterol), also known as Diazasterol, acts as a DHCR24 inhibitor and initiates a cascade of reactions in cortical neurons after being administered orally or via intraperitoneal injection.
    Azacosterol
  • HY-16771A
    Valbenazine tosylate 1639208-54-0 98%
    Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the Ki of 110-190 nM.
    Valbenazine tosylate
  • HY-16771B
    Valbenazine dihydrochloride 1639208-51-7 98%
    Valbenazine (NBI-98854) dihydrochloride is a VMAT2 inhibitor, used to treat tardive dyskinesia. Valbenazine dihydrochloride demonstrates potential benefit in alleviating symptoms associated with movement disorders resulting from chronic dopamine receptor blocking medications. Valbenazine dihydrochloride has been supported by evidence from preclinical models examining its role in the genetic factors linked to tardive dyskinesia.
    Valbenazine dihydrochloride
  • HY-167741
    Chlorisondamine 69-27-2 98%
    Chlorisondamine is a nicotinic antagonist that acts as a ganglionic blocker and has been utilized to evaluate the neurogenic contributions to blood pressure and sympathetic vasomotor tone in animal models. Chlorisondamine has demonstrated antihypertensive properties, primarily being assessed through its effects on blood pressure, cardiac output, and heart rate in various experimental settings, particularly in mice.
    Chlorisondamine
  • HY-167745
    DDR1-IN-9 1934246-20-4 99.64%
    DDR1-IN-9 is a selective inhibitor of DDR1 with significant kinase activity suppression, exhibiting a Kd value of 4.7 nM and an IC50 value of 9.4 nM. DDR1-IN-9 demonstrates reduced potency against a diverse panel of 400 nonmutated kinases, indicating its specificity. Additionally, DDR1-IN-9 shows favorable pharmacokinetic properties and potential therapeutic effects in a model of pulmonary fibrosis.
    DDR1-IN-9
  • HY-167822
    Caramboxin 1531600-36-8 98%
    Caramboxin is a neurotoxin that can cause acute kidney injury[2].
    Caramboxin
  • HY-167825
    Barakol 24506-68-1 98%
    Barakol is a major compound found in Cassia siamea. Barakol inhibits MMP-3 activity. Barakol potentiates the anti-metastatic effect of Doxorubicin (HY-15142). Barakol induces apoptosis, with ROS generation, increase in expression ratio of Bax/Bcl-2, and caspase-9 activation. Barakol has laxative, anxiolytic, CNS depressant, and antioxidant, anticancer effects.
    Barakol
  • HY-167840
    IMMH-010 maleate 2541982-47-0 98%
    IMMH-010 maleate is a prodrug that serves as a novel PD-L1 inhibitor, exhibiting potential antitumor activity for the treatment of neurological disorders and advanced malignant solid tumors. IMMH-010 maleate is rapidly converted to its active form, YPD-29B, following oral administration. IMMH-010 maleate is poised for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.
    IMMH-010 maleate
  • HY-167843
    Alborixin 57760-36-8 98%
    Alborixin is an inhibitor of the PI3K-AKT pathway that induces autophagy. It promotes the clearance of intracellular and extracellular amyloid-β by upregulating autophagy-related proteins (such as BECN1, ATG5, ATG7) and enhancing lysosomal activity, thereby reducing amyloid-β-mediated neurotoxicity. Alborixin shows potential for research in Alzheimer's disease.
    Alborixin
  • HY-167847
    IRI-514 147489-65-4 98%
    IRI-514 is a synthetic peptide analogue of Thymopentin (HY-N7122). IRI-514 plays a role in modulating behavioral and neuroendocrine responses to stress.
    IRI-514
  • HY-167849
    Sofpironium tosylate 2409055-48-5 98%
    Sofpironium (BBI 4000) tosylate is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium tosylate reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium tosylate also has a high afnity for the M1, M2, M4 and M5 subtypes.
    Sofpironium tosylate
  • HY-167850
    Noberastine maleate 111922-05-5 98%
    Noberastine maleate is a potent Histamine H1 antagonist. Noberastine maleate has specific peripheral antihistamine activity .
    Noberastine maleate
  • HY-167852
    GX-585 2098540-08-8 98%
    GX-585 is a sulfonamide analog that acts as a Nav1.7 channel inhibitor, demonstrating analgesic activity in treating neuropathic pain and inflammation.
    GX-585
  • HY-167865
    O-1269 336615-64-6 98%
    O-1269 is a partial agonist of cannabinoid receptor 1 (CB1R) with a Ki of 32 nM. O-1269 shows analgesic effects.
    O-1269
  • HY-167875
    Neflumozide 86636-93-3 98%
    Neflumozide (HRP 913) is an orally active benzisoxazole derivative and a potent dopamine antagonist with antipsychotic activity. Neflumozide can be utilized in psychosis research.
    Neflumozide
  • HY-167885
    SN-35210 free base 1450615-41-4 98%
    SN-35210 free base, an ester analogue, is designed for rapid offset via esterase-mediated hydrolysis.
    SN-35210 free base
  • HY-167893
    AGH-107 2172907-10-5 98%
    AGH-107 is a high selective and brain-penetrant agonist of 5-HT7 receptor, with a Ki of 6 nM and EC50 of 19 nM. AGH-107 exhibits high selectivity over related CNS targets, high metabolic stability and low toxicity in HEK-293 and HepG2 cell cultures.
    AGH-107
  • HY-167897
    UR-AK49 902154-32-9 98%
    UR-AK49 (compound 11) is a human histamine H1 and H2 receptor agonist. UR-AK49 has an EC50 of 23 nM in a GTPase assay with hH2R-Gsalpha fusion protein expressed in Sf9 insect cells. UR-AK49 can be used in neuro-related research.
    UR-AK49
  • HY-167898
    MeS-IMPY 955376-42-8 98%
    MeS-IMPY is a ligand of β-amyloid plaques. MeS-IMPY shows a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (Ki=7.93 and 8.95 nM, respectively). [11C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET).
    MeS-IMPY
Cat. No. Product Name / Synonyms Application Reactivity